FY2018 EPS Estimates for Proteostasis Therapeutics Inc (PTI) Lifted by Leerink Swann
Proteostasis Therapeutics Inc (NASDAQ:PTI) – Stock analysts at Leerink Swann raised their FY2018 earnings per share estimates for Proteostasis Therapeutics in a report released on Wednesday. Leerink Swann analyst J. Schwartz now forecasts that the company will earn ($1.49) per share for the year, up from their previous estimate of ($1.57). Leerink Swann currently has a “Outperform” rating and a $9.00 target price on the stock. Leerink Swann also issued estimates for Proteostasis Therapeutics’ FY2019 earnings at ($1.18) EPS and FY2020 earnings at ($1.20) EPS.
Proteostasis Therapeutics (NASDAQ:PTI) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.16. The business had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.38 million. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%.
Shares of Proteostasis Therapeutics (NASDAQ:PTI) opened at $2.52 on Monday. Proteostasis Therapeutics has a fifty-two week low of $1.41 and a fifty-two week high of $16.67.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP bought a new position in shares of Proteostasis Therapeutics during the second quarter worth $254,000. Jennison Associates LLC boosted its position in shares of Proteostasis Therapeutics by 6.2% during the second quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock worth $9,713,000 after purchasing an additional 120,575 shares in the last quarter. FMR LLC boosted its position in shares of Proteostasis Therapeutics by 2.3% during the second quarter. FMR LLC now owns 2,944,915 shares of the company’s stock worth $13,782,000 after purchasing an additional 66,111 shares in the last quarter. Bain Capital Public Equity Management LLC bought a new position in shares of Proteostasis Therapeutics during the second quarter worth $1,233,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Proteostasis Therapeutics by 17.3% during the first quarter. Bank of New York Mellon Corp now owns 34,964 shares of the company’s stock worth $273,000 after purchasing an additional 5,153 shares in the last quarter. 68.08% of the stock is currently owned by institutional investors.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.